Not to worry on the Prurisol front. Even if the 200mg signal led us astray, all of the arms showed minor and qualitative improvement for patients (less itchy plaques, minor improvement, etc) It doesn't have to match otezla. It could be sold for $50M and be developed by someone else as a very light weight first-line treatement for mild psoriasis.

Let's hope for an Otezla blowout but no need for fear.

Go IPIX!